| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
N-563 targets the immune system, specifically stimulating immune responses to enhance host defense against pathogens. As an analogue of deoxyspergualin, N-563 mimics the immunostimulatory activity of the parent compound. Deoxyspergualin is known to modulate immune function by affecting lymphocyte proliferation and cytokine production. N-563 promotes resistance to Candida albicans infection in mice. The compound's mechanism of action involves stimulation of immune responses, likely through the activation of macrophages, neutrophils, or other immune effector cells. The compound's molecular target may involve pathways related to immune cell activation and host defense against fungal pathogens.
|
|---|---|
| ln Vitro |
N-563 demonstrates in vitro activity as an immunostimulatory compound. The compound is an analogue of deoxyspergualin with immunostimulating activity. Its activity is typically assessed by measuring immune cell activation or cytokine production in response to treatment. N-563's ability to stimulate immune responses has been characterized in various in vitro systems using immune cells. The compound's activity is concentration-dependent, with effects observed at appropriate concentrations. N-563 is used as a research tool to study immune modulation and host defense mechanisms against fungal infections. Comprehensive in vitro activity data are available from research publications.
|
| ln Vivo |
In vivo, N-563 has demonstrated significant efficacy in enhancing resistance to Candida albicans infection. The compound promotes resistance to Candida albicans infection in mice. The protective effect of N-563 against C. albicans has been characterized in mouse models of fungal infection. N-563 is a deoxyspergualin mimetic that stimulates immune responses and enhances resistance to fungal pathogens. The compound's in vivo activity supports its potential for studying host defense mechanisms against fungal infections. Comprehensive in vivo efficacy studies have been reported in research publications.
|
| Enzyme Assay |
In vitro assays for N-563 typically involve measuring its immunostimulatory activity. Immune cells such as macrophages, dendritic cells, or lymphocytes are treated with varying concentrations of the compound. Cytokine production (TNF-alpha, IL-1beta, IL-6, IFN-gamma) is measured by ELISA or multiplex bead-based assays. Cell proliferation is assessed using [3H]-thymidine incorporation or CFSE dilution. Phagocytic activity of macrophages can be assessed using fluorescently labeled particles. The compound's structure and purity can be characterized using analytical methods. High-performance liquid chromatography (HPLC) and mass spectrometry are used to verify the molecular weight (359.42 g/mol) and chemical composition (C15H29N5O5). Purity (≥98%) is confirmed by HPLC analysis.
|
| Cell Assay |
In vitro cellular assays for N-563 are performed using immune cells such as macrophages, dendritic cells, or lymphocytes. Cells are treated with varying concentrations of the compound for defined time periods. Cytokine production is measured by ELISA or multiplex bead-based assays. Cell proliferation is assessed using [3H]-thymidine incorporation or CFSE dilution. Phagocytic activity is assessed using fluorescently labeled particles or bacteria. Cell surface marker expression (MHC class II, CD80, CD86) is measured by flow cytometry. Cytotoxicity is assessed in parallel using standard viability assays such as MTT to ensure that observed effects are not due to cell death. EC50 values for stimulation of immune responses are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for N-563 are conducted using mouse models of Candida albicans infection. Mice are infected with C. albicans and treated with N-563 via intraperitoneal injection or oral administration at various doses and schedules. Survival is monitored, and fungal burden in tissues (kidney, liver, spleen) is measured by colony-forming unit (CFU) counts. Cytokine levels in serum and tissues are measured by ELISA. Immune cell populations in spleen and blood are analyzed by flow cytometry. Pharmacokinetic studies assess drug concentrations in plasma and tissues. Animals are monitored for clinical signs and body weight. Efficacy is expressed as survival rate and reduction in fungal burden compared to vehicle-treated controls.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of N-563 have been characterized in preclinical studies. The compound has a molecular formula of C15H29N5O5 and a molecular weight of 359.42 g/mol. Its IUPAC name is 3-(4-(7-guanidinoheptanamido)-3-hydroxybutanamido)propanoic acid. The compound is soluble in DMSO and other organic solvents. Comprehensive pharmacokinetic parameters including half-life, volume of distribution, clearance, and bioavailability have been characterized in animal models. The compound's pharmacokinetic profile supports its use in preclinical studies of immunostimulation and host defense. Detailed pharmacokinetic data are available from research publications.
|
| Toxicity/Toxicokinetics |
N-563 is intended for laboratory research use only and has not undergone comprehensive clinical toxicology testing. As an immunostimulatory compound, N-563 would be expected to have effects on immune function. Standard in vitro cytotoxicity assays in cell lines are typically performed alongside efficacy studies to rule out nonspecific toxicity. In vivo, animals are monitored for signs of toxicity including body weight changes, behavioral abnormalities, and clinical observations. Comprehensive toxicological characterization including genotoxicity and repeated-dose toxicity studies has not been extensively reported. The compound is not approved for human use and is strictly intended for research purposes.
|
| Additional Infomation |
N-563 is an analogue of deoxyspergualin with immunostimulating activity. It is a deoxyspergualin mimetic that stimulates immune responses and enhances resistance to Candida albicans in mice. The compound has a molecular formula of C15H29N5O5 and a molecular weight of 359.42 g/mol. N-563 promotes resistance to Candida albicans infection in mice. The compound has not entered clinical trials and has not received regulatory approval for any indication. It is available from research chemical suppliers for non-clinical research purposes only.
|
| Molecular Formula |
C15H29N5O5
|
|---|---|
| Molecular Weight |
359.42126
|
| Exact Mass |
359.217
|
| CAS # |
140686-92-6
|
| PubChem CID |
9906849
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3g/cm3
|
| Index of Refraction |
1.566
|
| LogP |
1.658
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
25
|
| Complexity |
452
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(NCCC(O)=O)CC(O)CNC(CCCCCCNC(N)=N)=O
|
| InChi Key |
IFBKFXWWJPFRDV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H29N5O5/c16-15(17)19-7-4-2-1-3-5-12(22)20-10-11(21)9-13(23)18-8-6-14(24)25/h11,21H,1-10H2,(H,18,23)(H,20,22)(H,24,25)(H4,16,17,19)
|
| Chemical Name |
3-[[4-[7-(diaminomethylideneamino)heptanoylamino]-3-hydroxybutanoyl]amino]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :< 1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7823 mL | 13.9113 mL | 27.8226 mL | |
| 5 mM | 0.5565 mL | 2.7823 mL | 5.5645 mL | |
| 10 mM | 0.2782 mL | 1.3911 mL | 2.7823 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
